FSLR DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages First Solar, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FSLR

Rosen Law Firm is notifying investors in First Solar, PicS N.V., and Erasca of upcoming lead plaintiff deadlines in securities class action lawsuits. First Solar faces allegations of making false statements regarding tariff policy management and production facility impacts. The firm is encouraging investors who purchased securities during specified class periods to seek legal counsel.

08/02/2026, 4:49 PM • GlobeNewswire

PICS DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages PicS N.V. Investors to Secure Counsel Before Important August 4 Deadline in Securities Class Action – PICS

Rosen Law Firm is notifying investors of securities class action lawsuits against PicS N.V., Erasca, Inc., and Planet Fitness, Inc. The PicS lawsuit alleges false statements in IPO documents regarding credit evaluation procedures, loan quality, and undisclosed financial deterioration. Lead plaintiff deadlines are August 4, 2026 for PicS and August 10, 2026 for Erasca.

08/02/2026, 2:51 PM • GlobeNewswire

ERASCA DEADLINE: ROSEN, REGARDED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action – ERAS

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary focus is on Erasca, Inc., which allegedly made false and misleading statements about its lead oncology drug candidate ERAS-0015, claiming it was 'best-in-class' while failing to disclose improper comparisons to competitors and lacking reasonable basis. The firm is seeking lead plaintiffs with an August 10, 2026 deadline for Erasca and August 4, 2026 for PicS N.V.

08/02/2026, 2:36 PM • GlobeNewswire

Robbins LLP Reminds Erasca, Inc. Investors of the Pending Lead Plaintiff Deadline in the Securities Fraud Class Action; Contact the Firm to Learn About Your Rights

A securities fraud class action has been filed against Erasca, Inc. (NASDAQ: ERAS) for allegedly failing to disclose risks related to patent and trade secret violations. The lawsuit stems from Erasca's ERAS-0015 drug candidate, which Revolution Medicines claims infringes its patent and involves misappropriated trade secrets. The stock dropped from $21.49 to $19.15 per share following the disclosure on April 27, 2026. Investors have until August 10, 2026 to submit lead plaintiff papers.

07/31/2026, 10:28 AM • GlobeNewswire

ERASCA DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action – ERAS

Rosen Law Firm is reminding investors in Erasca, Inc. (NASDAQ: ERAS) who purchased stock between January 14, 2025 and April 26, 2026 of an August 10, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Erasca and its executives made false and misleading statements about its lead oncology drug candidate ERAS-0015, including improper comparisons to a competing drug and undisclosed patent disputes.

07/30/2026, 4:49 PM • GlobeNewswire

Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Insulet Corporation (NASDAQ: PODD); New Era Energy & Digital, Inc. (NASDAQ: NUAI) (formerly known as New Era Helium (NASDAQ: NEHC)); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Office announced investigations into multiple publicly traded companies on behalf of shareholders, alleging breaches of fiduciary duties and securities law violations. The investigations cover Erasca (misleading statements about ERAS-0015 drug candidate and patent infringement), Insulet (defective manufacturing controls leading to product recalls), New Era Energy & Digital (overstated project progress and fraudulent oil-and-gas schemes), Power Solutions International (overstated sales demand and understated manufacturing costs), Hub Group, Planet Fitness, Primoris Services, EquipmentShare.com, GPGI, Photronics, and Via Transportation. Shareholders who meet specific holding criteria may seek damages and corporate governance reforms at no cost.

07/29/2026, 8:43 AM • GlobeNewswire

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Law firm Kahn Swick & Foti, LLC has filed multiple class action securities lawsuits against Erasca, Inc., EquipmentShare.com Inc., and PROCEPT BioRobotics Corporation. Erasca faces allegations of failing to disclose material information regarding its ERAS-0015 product and improper patent comparisons. EquipmentShare.com and PROCEPT BioRobotics also face securities fraud claims. Investors have until specified deadlines to apply as lead plaintiffs.

07/28/2026, 11:33 PM • GlobeNewswire

ERAS INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - August 10, 2026 Deadline

Erasca, Inc. faces a securities class action lawsuit alleging that the company and its executives made false statements about its lead drug candidate ERAS-0015. The lawsuit claims Erasca's preclinical data involved improper comparisons and failed to disclose patent infringement risks from Revolution Medicines. Following disclosure of a patent assertion letter and adverse clinical trial data on April 27, 2026, Erasca's stock fell approximately 59% over two trading days. Investors with substantial losses can seek lead plaintiff status by August 10, 2026.

07/28/2026, 7:45 AM • GlobeNewswire

ERASCA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS

A securities class action lawsuit has been filed against Erasca, Inc. and its executives for allegedly making false and misleading statements about its lead oncology drug candidate ERAS-0015. The company is accused of improperly comparing its drug to a competitor's candidate and failing to disclose patent and trade secret disputes. Investors who purchased Erasca stock between January 14, 2025 and April 26, 2026 may be eligible for compensation. The deadline to serve as lead plaintiff is August 10, 2026.

07/27/2026, 5:54 PM • GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors that a Class Action Lawsuit Has Been Filed Against Erasca and Encourages Investors to Contact the Firm Before August 10th

A class action lawsuit has been filed against Erasca, Inc. alleging the company made false statements about its ERAS-0015 drug candidate based on improper comparisons and lacking reasonable basis for positive claims. The lawsuit was triggered after Revolution Medicines alleged patent infringement and trade secret misappropriation on April 28, 2026, causing Erasca's stock to plunge 48% from $19.15 to $9.90 per share. Investors who purchased shares between January 14, 2025 and April 26, 2026 have until August 10, 2026 to apply as lead plaintiff.

07/23/2026, 5:53 PM • GlobeNewswire

ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors who purchased Erasca, Inc. securities between January 14, 2025 and April 26, 2026 to join a class action lawsuit alleging securities fraud. The complaint claims Erasca made false and misleading statements regarding its ERAS-0015 preclinical data, which was based on improper comparisons and lacked proper basis, potentially violating patent protections.

07/20/2026, 1:53 PM • GlobeNewswire

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS

Rosen Law Firm is notifying investors who purchased Erasca, Inc. (ERAS) stock between January 14, 2025 and April 26, 2026 about a securities class action lawsuit. The lawsuit alleges that Erasca and its executives made false and misleading statements about its lead oncology drug candidate ERAS-0015, including improper comparisons to a competing drug and undisclosed patent disputes. The deadline to serve as lead plaintiff is August 10, 2026.

07/18/2026, 7:56 PM • GlobeNewswire

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS

Rosen Law Firm is reminding investors who purchased Erasca, Inc. common stock between January 14, 2025 and April 26, 2026 of an August 10, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Erasca and its executives made false and misleading statements about its lead oncology drug candidate ERAS-0015, including improper comparisons to a competing drug and undisclosed patent disputes.

07/15/2026, 12:52 PM • GlobeNewswire

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Kahn Swick & Foti, LLC announces a class action securities lawsuit against Erasca, Inc. for investors who purchased shares between January 14, 2025 and April 26, 2026. The lawsuit alleges that Erasca and its executives failed to disclose material information, including that preclinical data for ERAS-0015 was based on improper comparisons and placed the company at risk of patent violations. The application deadline to request lead plaintiff status is August 10, 2026.

07/14/2026, 10:42 PM • GlobeNewswire

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in Erasca, Inc. Lawsuit - ERAS

Erasca, Inc. faces a securities class action lawsuit alleging that CEO Jonathan Lim and CFO David Chacko certified misleading statements about the ERAS-0015 drug trial while the company raised $258.8 million from investors. The stock collapsed 53.9% after disclosures revealed patent infringement allegations and a patient death. The lead plaintiff deadline is set for August 10, 2026.

07/14/2026, 9:56 AM • GlobeNewswire